Mode
Text Size
Log in / Sign up

Cohort study compares homocysteine and uric acid levels in Parkinson's disease-related and post-stroke cognitive impairment.

Cohort study compares homocysteine and uric acid levels in Parkinson's disease-related and post-stro…
Photo by Cht Gsml / Unsplash
Key Takeaway
Note potential metabolic differences between Parkinson's and post-stroke cognitive impairment requiring prospective validation.

This observational cohort study evaluated metabolic profiles in patients diagnosed with cognitive impairment. The population comprised 60 patients with Parkinson's disease-related cognitive impairment and 60 patients with post-stroke cognitive impairment admitted to the Department of Neurology at Yangjiang Hospital of Traditional Chinese Medicine. Follow-up duration was not reported in the study design.

Primary outcomes included homocysteine (Hcy) and uric acid (UA) levels. The PD-CI group exhibited significantly higher Hcy levels with an adjusted mean difference of 2.55 μmol/L (95% CI: 0.23–4.87, p = 0.032). Conversely, UA levels were significantly lower in PD-CI with an adjusted mean difference of −34.66 μmol/L (95% CI: −63.87 to −5.46, p = 0.020). Hcy negatively correlated with MMSE scores in the overall sample (r = −0.309, p = 0.001). The association of Hcy with MMSE was numerically stronger in the PD-CI group (r = −0.456), though the p-value was not reported. UA levels were independently associated with disease type.

Safety data regarding adverse events, serious adverse events, and discontinuations were not reported. The study is limited as an exploratory cross-sectional analysis requiring validation in prospective studies. Findings suggest potential differences in metabolic profiles and may offer new insights for clinical differential diagnosis, though causality cannot be established. Funding or conflicts of interest were not reported.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
To compare homocysteine (Hcy) and uric acid (UA) levels between patients with Parkinson’s disease with cognitive impairment (PD-CI) and those with post-stroke cognitive impairment (PS-CI), and to analyze the correlation of these biomarkers with cognitive function and their heterogeneity across different disease types. Patients diagnosed with cognitive impairment who were admitted to the Department of Neurology at Yangjiang Hospital of Traditional Chinese Medicine between January 2025 and December 2025 were included (60 PD-CI; 60 PS-CI). Blood Hcy and UA levels were uniformly measured, and cognitive function was assessed using the Mini-Mental State Examination (MMSE). Covariance analysis compared biomarker level differences between groups. Spearman correlation analysis and multivariate linear regression models with interaction terms explored the relationship between biomarkers and MMSE scores. Binary logistic regression identified factors independently associated with disease type. After adjusting for confounding factors, the PD-CI group exhibited significantly higher Hcy levels (adjusted mean difference: 2.55 μmol/L, 95% CI: 0.23–4.87, p = 0.032), while UA levels were significantly lower (adjusted mean difference: −34.66 μmol/L, 95% CI: −63.87 to −5.46, p = 0.020). In the overall sample, Hcy negatively correlated with MMSE (r = −0.309, p = 0.001). This association was numerically stronger in the PD-CI group (r = −0.456, p  Patients with PD-CI and PS-CI exhibit distinct metabolic profiles, with the PD-CI group characterized by elevated Hcy and low UA levels. Although elevated Hcy is a common factor associated with cognitive impairment in both conditions, UA levels in this cohort were independently associated with PD-CI (relative to PS-CI), not with MMSE scores. These findings suggest potential differences in metabolic profiles and may offer new insights for clinical differential diagnosis. As an exploratory cross-sectional analysis, these findings require validation in prospective studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.